Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9742279 | 0.92 | NAAA (0.41) | CYP2D6CYP3A4ALDH1A1MAPTPOLB | |
| SCHEMBL29851305 | 0.91 | CYP3A4 (0.36) | CYP2D6CYP3A4ALDH1A1MAPTPOLB | |
| SCHEMBL1983658 | 0.84 | TSHR (0.32) | CYP2D6MAPTLMNATSHRCYP1A2 | |
| SCHEMBL28275 | 0.78 | LOXL2 (0.32) | TDP1L3MBTL1 | |
| SCHEMBL15648671 | 0.77 | BDKRB2 (0.36) | CYP2D6CYP3A4ALDH1A1MAPTLMNA | |
| SCHEMBL15648819 | 0.77 | BDKRB2 (0.36) | CYP2D6CYP3A4ALDH1A1MAPTLMNA | |
| SCHEMBL276811 | 0.77 | LTA4H (0.38) | TSHRTDP1SMN1; SMN2NPSR1 | |
| SCHEMBL154603 | 0.76 | L3MBTL1 (0.49) | CYP2D6CYP3A4ALDH1A1POLBHDAC3 | |
| SCHEMBL29851135 | 0.76 | L3MBTL1 (0.49) | CYP2D6CYP3A4ALDH1A1POLBHDAC3 | |
| SCHEMBL1452840 | 0.76 | HTT (0.38) | CYP3A4ALDH1A1LMNANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209955-A | Carborane violet essence derivative, metal supermolecule polymer thereof, synthetic method and application | 西安交通大学 | 2021-01-12 | — | — | CN | claimed |
| CN-110872268-A | Isocoumarin derivative and preparation method and medicinal application thereof | 复旦大学 | 2020-03-10 | — | — | CN | claimed |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-5488055-A | ADMINISTERING GMP HOSPHODIESTERASE INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | SANOFI WINTHROP INC. (US) | 1996-01-30 | — | — | US | disclosed |
| WO-1995034564-A1 | PIRYDYL IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-12-21 | — | — | WO | disclosed |
| WO-1995021838-A1 | PYRIDYL IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-08-17 | — | — | WO | disclosed |
| EP-0290591-B1 | MATERIALS WITH NITROGENOUS SIX-MEMBERED RINGS | MERCK PATENT GmbH (DE) | 1991-03-13 | — | — | EP | disclosed |
| US-4959363-A | HERPES VIRUS | STERLING DRUG INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0348497-A1 | NON-LINEAR OPTICAL MATERIAL CONTAINING A HEMICYANINE COMPOUND AND PROCESS FOR PRODUCING IT | MERCK PATENT GmbH (DE) | 1990-01-03 | — | — | EP | disclosed |
| WO-1989005843-A1 | NON-LINEAR OPTICAL MATERIAL CONTAINING A HEMICYANINE COMPOUND AND PROCESS FOR PRODUCING IT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-06-29 | — | — | WO | disclosed |
| EP-0290591-A1 | MATERIALS WITH NITROGENOUS SIX-MEMBERED RINGS. | MERCK PATENT GMBH (DE) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988004305-A1 | MATERIALS WITH NITROGENOUS SIX-MEMBERED RINGS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | CYP2D6 4501/4885CYP3A4 4537/4885ALDH1A1 3319/4885 |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | CYP2D6 47/4885CYP3A4 448/4885ALDH1A1 824/4885 |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | CYP2D6 4501/4885CYP3A4 4537/4885ALDH1A1 3319/4885 |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | XPO1, XPOT, CSE1L | CYP2D6 1343/4885CYP3A4 1846/4885ALDH1A1 3320/4885 |
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | CYP2D6 2471/4885CYP3A4 4457/4885ALDH1A1 2998/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | CYP2D6 923/4885CYP3A4 1868/4885ALDH1A1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.